Lilly Reports Solid First-Quart...(----- ------------ Zyprexa(R) ...)

Zyprexa(R) $1,120.2 $1,108.0 1 %

Cymbalta 605.1 441.8 37 %

Gemzar(R) 426.2 376.9 13 %

Humalog(R) 407.4 339.5 20 %

Cialis(1) 336.9 193.1 74 %

Evista(R) 261.1 263.8 (1)%

Humulin(R) 257.7 225.8 14 %

Alimta 247.2 187.8 32 %

Forteo 185.0 153.4 21 %

Strattera 148.0 139.9 6 %

Total Sales - Reported $4,807.6 $4,226.1 14 %

Total Sales - Pro forma $4,807.6 $4,298.8 12 %

(1) These amounts represent the reported Cialis sales in Lilly's

financial statements and do not include Cialis sales from the

joint-venture countries prior to the ICOS acquisition on January 29,

2007. Total worldwide Cialis sales for the first quarter of 2008 of

$336.9 million represent 27 percent growth over the first quarter of

2007.

Significant Events Over the Last Three Months

-- On April 1, 2008, John C. Lechleiter, Ph.D., assumed the role of chief

executive officer of Eli Lilly and Company, replacing Sidney Taurel.

Taurel will remain chairman of the company's board of directors until

December 31, 2008, at which time he will retire from the board and from

the company.

-- The company terminated development of its AIR(R) Insulin program, which

was being conducted in partnership with Alkermes, Inc. The program had

been in Phase III clinical development as a potential treatment for

type 1 and type 2 diabetes. Lilly noted that this decision is not a

result of any observations during AIR Insulin trials relating to the

safety of the p
'/>"/>